What is CBG? Cannabigerol and CBGA explained
What is CBG, and why is it often called the ‘mother of cannabinoids’? Cannabigerol, abbreviated to CBG, is a naturally occurring component of the hemp plant. More precisely, however, that common expression refers to its acidic precursor, CBGA. Understanding this distinction helps put many claims about CBG into context.
Here you will learn how CBG forms, how it differs from CBD and what the research to date actually allows us to conclude. The focus is on accessible explanations and a careful assessment of the strength of study evidence, rather than promises about the health effects of products.
Quick navigation: CBG and CBGA · CBG and CBD · Preclinical research · Human study · Study checklist · Frequently asked questions · Conclusion · Sources
CBG and CBGA: one letter makes an important difference
CBGA stands for cannabigerolic acid. In the plant, it is a starting material for several cannabinoid acids. For example, particular enzymes convert CBGA into CBDA, the acidic precursor of CBD. CBG and CBGA are therefore related but different molecules. Saying that ‘CBG simply turns into CBD in the plant’ oversimplifies this relationship. Taura and colleagues' paper on CBDA synthase describes one of these enzymatic steps.
CBGA can become CBG through decarboxylation. Carbon dioxide is released in this process, for example under suitable heat exposure. This chemical conversion differs from the enzymatic formation of CBDA. An experimental investigation of decarboxylation illustrates the differences between acidic and neutral cannabinoids.
CBG and CBD: similarly named, not interchangeable
CBG means cannabigerol, and CBD means cannabidiol. Both are plant-derived cannabinoids and are not equivalent to the characteristic THC ‘high’. This does not establish that they have identical properties or that every product containing CBG or CBD is free from THC. A particular product's composition must be assessed from its own information and analytical data.
Research findings must not be transferred between these substances either: a result concerning CBD is not evidence about CBG. The same applies to investigations of CBGA or chemically modified CBG derivatives. The substance actually studied is always decisive. For an introduction to cannabidiol, visit our CBD information page.
What does CBG research investigate?
Some CBG research uses cells or animal models. A preclinical study by Borrelli and colleagues, for example, investigated inflammatory parameters in an experimental model of intestinal inflammation in mice. Such work provides indications about biological relationships. It does not establish successful treatment in people with bowel diseases.
A simple sequence helps put the evidence into context: a response observed in cells initially raises a research question. Subsequent human investigations must establish whether the finding holds under different conditions and what risks arise. A promising mechanism is therefore not yet an established medical application.
A human study of CBG: interesting but limited
In 2024, a double-blind, placebo-controlled crossover study by Cuttler and colleagues was published involving 34 healthy adults with previous cannabis experience. The investigation was conducted over Zoom. It compared short-term changes after a CBG preparation and a placebo.
Overall, participants reported a greater reduction in subjective anxiety with CBG; a difference in stress emerged at one particular measurement time. This is an interesting research signal. However, the study examined neither long-term treatment nor people with diagnosed anxiety disorders. Its small sample, brief observation period and particular participant group limit generalisability. The publication also discloses conflicts of interest.
The conclusion matters: this study justifies further research, not a general recommendation of CBG for treating anxiety, stress or other symptoms. Nor does it guarantee the safety of long-term use or of any commercial product.
How to recognise careful statements about CBG
Transparent information states both positive findings and their limitations. Pay particular attention to these questions:
Was CBG itself investigated, or a mixture containing other substances?
Was the research conducted in cells, animal models or humans?
How large was the investigation, and was there a comparison group?
Did it measure a short-term subjective experience or a clinical treatment outcome?
Are adverse effects, funding and conflicts of interest described?
Personal accounts can convey individual impressions. They do not reliably establish what caused a change. A high percentage on a bottle does not replace evidence of efficacy either. Concentration, composition and medical evidence answer different questions.
Frequently asked questions about cannabigerol
Is CBG the same as CBGA?
No. CBGA is cannabigerolic acid; CBG is its neutral form after decarboxylation. These terms should not be treated as equivalent in texts or analytical reports.
Is CBG better than CBD?
A blanket ranking is not scientifically meaningful. They are different substances with different evidence bases. A specific research question and suitable comparative studies would be needed.
Does ‘non-intoxicating’ mean ‘risk-free’?
No. These terms describe different properties. The absence of a characteristic THC ‘high’ does not establish general safety or rule out drug interactions.
Conclusion: understand the terminology and interpret research carefully
CBG is a distinct cannabinoid. Distinguishing it from CBGA is essential to understanding its formation and context. Early human research complements preclinical work but leaves many questions unanswered. Paying attention to the substances, methods and limitations studied provides a much more reliable picture than blanket lists of effects.
Explore further on our pages Cannabigerol: fundamentals and research and The endocannabinoid system. Find more articles in the Parmorcan® blog.
Please note: this article provides general information. It does not replace medical advice, diagnosis or treatment and contains no recommendations for ingestion or dosage. The cited studies do not demonstrate a health benefit of products in the Parmorcan® shop.
Sources and further evidence
The following sources are already linked in the text. The short English descriptions are provided for orientation; the original titles and bibliographic details are available in the linked publications.
Comments